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Introduction: DNA methyltransferase 3B (DNMT3B) contributes to 
de novo DNA methylation and its overexpression promotes tumori-
genesis. However, whether DNMT3B is upregulated by transcrip-
tional deregulation remains unclear.
Methods: We studied the transcriptional repression of DNMT3B by 
forkhead O transcription factor 3a (FOXO3a) in lung cancer cell, 
animal, and clinical models.
Results: The results of luciferase reporter assay showed that FOXO3a 
negatively regulated DNMT3B promoter activity by preferentially 
interacting with the binding element FOXO3a-E (+166 to +173) of 
DNMT3B promoter. Ectopically overexpressed FOXO3a or com-
bined treatment with doxorubicin to induce FOXO3a nuclear accu-
mulation further bound at the distal site, FOXO3a-P (−249 to −242) 
by chromatin-immunoprecipitation assay. Knockdown of FOXO3a 
resulted in an open chromatin structure and high DNMT3B mRNA 
and protein expression. Abundant FOXO3a repressed DNMT3B 
promoter by establishing a repressed chromatin structure. Note that 
FOXO3a is a degradation substrate of MDM2 E3-ligase. Cotreatment 
with doxorubicin and MDM2 inhibitor, Nutlin-3, further enforced 
abundant nuclear accumulation of FOXO3a resulting in decrease 
expression of DNMT3B leading to synergistic inhibition of tumor 
growth and decrease of methylation status on tumor suppressor 
genes in xenograft specimens. Clinically, lung cancer patients with 
DNMT3B high, FOXO3a low, and MDM2 high expression profile 
correlated with poor prognosis examined by immunohistochemistry 
and Kaplan-Meier survival analysis.
Conclusions: We reveal a new mechanism that FOXO3a transcrip-
tionally represses DNMT3B expression and this regulation can be 
attenuated by MDM2 overexpression in human lung cancer model. 
Cotreatment with doxorubicin and Nutlin-3 is a novel therapeutic 
strategy through epigenetic modulation.
Key Words: DNMT3B, FOXO3a, MDM2, Doxorubicin, Nutlin-3, 
Prognosis, Lung cancer
(J Thorac Oncol. 2014;9: 1305–1315)
In the past 10 years, aberrant DNA methylation in cancer cells has been widely studied. The cancer genome shows genome-
wide hypomethylation and accompanies by hypermethylation 
of CpG islands in the tumor suppressor genes (TSGs).1,2 The 
promoter hypermethylation of CpG islands in TSGs is asso-
ciated with transcriptional silencing and appears to promote 
tumor formation and progression.2 DNA methylatransferases 
(DNMTs) are the enzymes that methylate C5 position of 
cytosine bases in CpG dinucleitides, including five members 
(DNMT1, 2, 3A, 3B, and 3L) distinct by their different func-
tions.3,4 Among them, DNMT3 family generates the initial 
methylation pattern de novo.5,6 DNMT3B knockout mice show 
global demethylation of DNA and die during embryogenesis 
or during the first week after birth.5 Loss of DNMT3B activity 
in human leads to immunodeficiency, centromere instability, 
and facial anomalies syndrome, a genetic disorder accompa-
nied by low methylation in pericentromeric satellite regions.7 
DNMT3B overexpression either at mRNA or protein level has 
been shown in several human cancer cells, including lung, 
hepatoma, colorectal, retinoblastoma, and breast cancers.8–12 
Some oncogenic pathways such as PI3K/AKT and estrogen 
receptor signaling have been reported to be involved in stimu-
lating the DNMT3B expression.13,14 However, the underlying 
mechanisms involved in DNMT3B transcriptional regulation 
remains to be elucidated.
Recent study shows that DNMTs transcript levels neg-
atively correlated with forkhead O transcription factor 3a 
(FOXO3a) in oocyte development, implicating that FOXO3a 
may transcriptionally repress the DNMT genes.15 FOXO3a 
belongs to a large protein family of transcriptional regulators 
characterized by a conserved DNA-binding domain termed 
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the “forkhead-box”.16,17 To date, many reports indicate a tumor 
suppressor role of FOXO3a. For example, ectopic overexpres-
sion of FOXO3a significantly impairs tumor growth in cell 
and xenograft models in breast cancer and promotes apop-
tosis in leukemia and prostate cancer cells.18,19 In addition, 
repression of FOXO3a transcriptional activity in cancer cells 
results in promotion of angiogenesis and tumor progression.20 
FOXO3a has been shown to transcriptionally upregulate 
apoptotic-related genes such as p27, Bim, and Fas ligand.18,21,22 
In contrast, FOXO3a could transcriptionally repress miR21, 
which suppresses the expression of Fas ligand.23 FOXO3a is 
also a transcriptional repressor of Skp2 gene expression to 
inhibit Skp2 SCF E3 ligase toward p27 ubiquitination and 
degradation.24 Of note, gene deletion of FOXO3a is found in 
early-stage lung adenocarcinoma of smokers and tobacco car-
cinogen-initiated lung tumors in mice.25,26 Restored FOXO3a 
in FOXO3a-deficient lung cancer cells increases the cell apop-
totic response to nicotine-derived nitrosamino ketone-medi-
ated DNA damage.27 The last-mentioned studies implicate that 
loss of FOXO3a may contribute to lung cancer pathogenesis.
Many activated oncogenic kinase pathways in human 
cancers, including AKT, ERK, and IKKβ had been reported 
to target FOXO3a regulation.28–30 These oncogenic kinases 
could phosphorylate FOXO3a at different sites retaining it in 
the cytoplasm localization and subsequently leading to its deg-
radation. AKT-dependent phosphorylation of human FOXO3a 
at Thr31, Ser253, and Ser315 promotes FOXO3a interaction with 
14-3-3, the scaffold protein within the cytoplasm, and elicits the 
export of FOXO3a from the nucleus into the cytoplasm. On the 
other hand, ERK phosphorylates FOXO3a at Ser294, Ser344, and 
Ser425 thereby enhancing the interaction with MDM2 through 
conformational change and results in promoting degradation 
of FOXO3a through the ubiquitination-proteasome-mediated 
pathway. It is worth mentioning that doxorubicin, a topoisom-
erase II inhibitor, had been reported to induce FOXO3a trans-
location into the nucleus and activate FOXO3a to regulate the 
expression of downstream genes.23,31 Based on the observation 
of an inverse expression of DNMT and FOXO3a and frequent 
loss of FOXO3a in cancer cells, the present study aims to eluci-
date the mechanism of transcriptional repression of DNMT3B 
by FOXO3a in lung cancer cell, xenograft, and patient models. 
Given that FOXO3a the potent antitumor growth activity, we 
proposed to also investigate whether promotion of FOXO3a 
nuclear accumulation using the drugs doxorubicin and 
Nutlin-3, an MDM2 inhibitor32 could reactivate the DNMT3B 
transcriptional regulation by FOXO3a thereby reversing the 
DNA methylation status of TSGs.
MATERIALS AND METHODS
Cell Culture
Lung cancer cell lines A549 and CL1-5 were cultured in 
Dulbecco’s Modified Eagle’s Medium (Invitrogen, Carlsbad, 
CA) and incubated in a humidified incubator containing 5% 
CO
2
. All cells were supplemented with 10% fetal bovine 
serum (Invitrogen) and 1% penicillin/streptomycin (100 units/
ml penicillin and 100 μg/ml streptomycin, Invitrogen). A549 
cell line was purchased from the American Type Culture 
Collection (Manassas, VA). CL1-5 cell line was obtained 
from Dr. Pan-Chyr Yang (Department of Internal Medicine, 
Medical College, National Taiwan University, Taiwan).
Treatment with Doxorubicin and Nutlin-3
CL1-5 and A549 cells were cultured overnight before 
exposure to 2 μM doxorubicin (Sigma-Aldrich, MO) for 
4 hours to induce nuclear localization of FOXO3a. A549 cells 
were treated with 5 μM Nutlin-3 (Sigma-Aldrich) for 16 hours 
to inhibit MDM2-mediated FOXO3a degradation. In com-
bined treatment, Nutlin-3 was added first and doxorubicin was 
added at the final 4 hours.
Plasmid, RNAi, Transfection and 
Promoter Activity Assay
The expression vectors and interference RNA (RNAi) 
used in the present study are shown in SDC 1 (http://links.
lww.com/JTO/A616) and SDC 2 (http://links.lww.com/
JTO/A617). Transfection of RNAi was carried out with 
Lipofectamine 2000 (Invitrogen) according to the manufac-
ture’s protocol. Transfection of pGL4-derivatives promoter 
construct vectors, pGFP, and pGFP-FOXO3a was carried 
out using Turbofect (MBI Fermentas, Flamborough, Ontario, 
Canada) according to the manufacture’s protocol.
CL1-5 cells and A549 cells were transfected with si-
FOXO3a for 24 hours or FOXO3a expression vector for 
18 hours. Then 2 μg/well of pGL4 vector, pGL4-full length 
(−483 to +315), pGL4-P region (−483 to +50), or pGL4-E 
region (+31 to +315) of DNMT3B promoter was transfected 
along with 1 μg/well of pGL4-renilla construct (as internal 
control) and incubated for another 24 hours. Dual luciferase 
reporter assay system (Promega Corp., Madison, WI) was 
used to perform the luciferase assay according to the manufac-
turer’s instruction. The promoter constructs were generated by 
polymerase chain reaction (PCR) cloning and the sequences 
of the primers used are listed in SDC 3 (http://links.lww.com/
JTO/A618).
RNA Extraction and Quantitative Reverse-
Transcriptase PCR (RT-qPCR) Assay
Total RNA were extracted using Trizol reagent 
(Invitrogen). Total RNA (4 μg) was reverse transcribed into 
cDNA using SuperScript reverse tanscriptase (Invitrogen) and 
amplified using SYBR Green PCR Master Mix (Roche, Palo 
Alto, CA) and specific primers for each candidate genes. The 
primer sequences and the annealing temperature are listed in 
SDC 3 (http://links.lww.com/JTO/A618). The relative amount 
of amplified gene products was calculated using the relative 
standard curve method and normalized to β-actin as detected 
in the same run.
Quantitative Methylation-
Specific PCR (qMSP) Assay
Sodium bisulfite modification of genomic DNA was per-
formed using EZ DNA Methylation-Gold kit (Zymo Research, 
Irvine, CA) according to the manufacturer’s protocols. The 
qMSP assay was conducted using FastStart Universal SYBR 
Green Master Mix (Roche) and StepOnePlus Real-Time PCR 
1307Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 FOXO3a Transcriptionally Represses DNMT3B
System (Applied Biosystems, Foster City, CA). The total 
20 μl reaction mix included 1 μl bisulfite-treated DNA 
(50 ng), 0.5 μl forward methylation-specific primer (10 μM), 
0.5 μl reverse methylation-specific primer (10 μM), 10 μl 
SYBR Green Master Mix, and 8 μl ddH
2
O. The qPCR condi-
tions were initiated with a denaturing step at 95°C for 10 min-
utes, followed by 45 cycles at 95°C for 20 seconds, 65°C for 
20 seconds, and 72°C for 20 second. The fluorescence inten-
sity was obtained and analyzed by StepOnePlus System. DNA 
of normal lung cell IMR90 and fully methylated IMR90 DNA 
treated with SssI enzyme served as control for unmethylated 
and methylated alleles, respectively. We generated serial dilu-
tion (100%, 75%, 50%, 25%, and 0% DNA methylation) of 
standards using methylated DNA (SssI-treated IMR90 DNA) 
and unmethylated DNA (IMR90 DNA), and performed 
qMSP analyses using BLU, RASSF1A, SLIT2, and β-actin 
genes using specific primers as listed in Supplemental Digital 
Content 3 (http://links.lww.com/JTO/A6180). For the internal 
reference gene β-actin, the primers were designed to amplify 
and detect a region devoid of CpG nucleotides. Thus, amplifi-
cation of β-actin by qMSP occurs independently of its methyl-
ation status. The qPCR analysis for methylation status of BLU, 
RASSF1A, and SLIT2 genes were normalized to β-actin, and 
the relative methylation ratio was identified by 2−△△CT determi-
nation method.
Chromatin-Immunoprecipitation 
(ChIP) and Western Blot Assays
Chromatin DNA were immunoprecipitated at 4°C for 
16 to 18 hours using anti-FOXO3a, anti-HDAC3, anti-tri-
methylation of histone 3 lysine 27 (H3K27me3), anti-acety-
lation of histone 3 lysine 9 and 14 (H3Ace), and normal IgG 
(as negative control). Immunoblotting was performed using 
antibodies against FOXO3a, DNMT3B, MDM2, or HDAC3. 
β-actin was an loading control. Antibodies and conditions are 
listed in SDC 4 (http://links.lww.com/JTO/A619). The primer 
sequences and the annealing temperature to amplify the ChIP-
DNA are listed in SDC 3 (http://links.lww.com/JTO/A618).
Immunofluorescence Staining and 
Confocal Microscopic Analysis
Cells were cultured overnight and treated with or with-
out 2 μM doxorubicin at indicated times. Cells were then 
incubated with primary antibody and followed by incubation 
with DAPI and fluorescent secondary antibody for 1 hour and 
images were obtained by an OLYMPUS FV1000 confocal 
microscope (Olympus America Inc., Melville, NY) to detect 
localization of FOXO3a. Antibodies and conditions are listed 
in SDC 4 (http://links.lww.com/JTO/A6190).
Immunohistochemistry Assay
Paraffin blocks of tumors were sectioned into 5 μm 
slices and processed using standard deparaffinization and 
rehydration techniques. Antibodies against FOXO3a, 
DNMT3B, and MDM2 were used and conditions for each 
are listed in SDC 4 (http://links.lww.com/JTO/A6190). The 
sections were then sequentially incubated with biotinylated 
secondary antibody for 40 minutes followed by streptavidin-
horseradish peroxidase for 20 minutes. 3, 3′-diaminobenzidine 
tetrahydrochloride (DAKO LSAB kit K0675, Dako, Glostrup, 
Denmark) was used as the chromagen. The evaluation of the 
immunohistochemistry staining was conducted blindly, without 
prior knowledge of the clinical and pathologic characteristics 
of the cases or treatments given to the mice. The surrounding 
non-neoplastic stroma served as an internal control for each 
slide. The staining “intensity” measurements were translated 
into the four-tier system as strong (3+), moderate (2+), weak 
(1+), or negative (–) staining. DNMT3B stains were graded as 
“overexpression” if nucleus staining “intensity” were 2+ and 
3+. FOXO3a stains were graded as “overexpression” if nucleus 
staining “intensity” were 1+. For MDM2 protein expression 
level, the stains were graded as “overexpression” if more than 
50% tumor cells were immunostaining-positive.
Xenograft Mice Experiments
Female BALB/cAnN.Cg-Foxnlnu/CrlNar mice, 4–5 
weeks of ages, were raised in pathogen-free conditions 
within the animal resources center at National Cheng Kung 
University after obtaining appropriate institutional review 
board permission. The animals were implanted subcutane-
ously with 5 × 106 A549 cells in 0.1 ml Hanks’ balanced 
salt solution in one flank per mouse. The size of the tumor 
mass was measured and the tumor volume was calculated 
as 1/2 × length × width2 in mm3. When tumors attained a 
mass ~50 mm3, the animals were treated intraperitoneally 
with doxorubicin (1 mg/kg; twice per week for 3 weeks; from 
Selleck, Houston, TX) or/and Nutlin-3 (20 mg/kg; triplicate 
per week for 3 weeks; from Selleck) or DMSO as control. 
The tumor size and body weight of mice were measured on 
days 1 and 5 of each week till the mice were killed by cervi-
cal dislocation. Resected tissues were fixed with 10% form-
aldehyde for at least over night before embedded in paraffin 
for histopathologic examination. Tumors were harvested and 
subjected to immunohistochemistry analyses or qMSP for 
TSGs as described above.
Patient Information
Surgically resected tumor samples from 74 patients 
diagnosed with primary lung cancer admitted to Veterans 
General Hospital, Taipei, were collected between 1993 and 
2007 after obtaining appropriate institutional review board 
permission and informed consent from patients. The follow-
up of 72 patients was performed at 2-month intervals in the 
first year after surgery and at 3-month intervals thereafter at 
outpatient clinics or by routine phone calls. The mean follow-
up period for all patients was 50 months (range 1–96 months). 
For the 37 patients who survived the follow-up period (cen-
sored patients), the mean follow-up period was 78 months. 
For the 35 patients who died during the follow-up period, the 
mean follow-up period was approximately 30 months.
Statistical Analysis
The SPSS program (SPSS Inc. Chicago, IL) was used 
for all statistical analysis. The two-tailed student t test was 
used to analyze the changes in expression and chromatin 
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marks levels in cell models. The combination index (CI) 
was calculated according to CalcuSyn software. CI values 
less than 1.0 suggested synergy, and values = 1.0 indicated 
additivity, whereas values more than 1.0 suggested antago-
nism. The Pearson χ2 test was used to analyze the correlation 
between protein expression levels in lung cancer patients. 
Survival curves were calculated according to the Kaplan-
Meier method, and comparison was performed using the 
log-rank test. Differences were considered significant when 
p less than 0.05 (*), p less than 0.01 (**) or p less than 0.001 
(***). Three independent experiments for cell studies and 
six mice per group for animal studies were analyzed unless 
indicated otherwise.
RESULTS
FOXO3a Represses the mRNA and 
Protein Expression of DNMT3B
As model cells, A549 and CL1-5 lung cancer cells, 
which showed low and high FOXO3a basal expression level, 
respectively, in cytoplasm and nucleus (Fig. 1A, DMSO 
panels) have been selected, whereas doxorubicin enforced 
FOXO3a into nuclei in both cells as seen in immunofluores-
cence staining assay (Fig. 1A, doxorubicin panels). These 
two cells were used for further FOXO3a overexpression and 
knockdown experiments.
The RT-qPCR and Western blot assays showed that 
overexpression of FOXO3a by doxorubicin treatment or GFP-
FOXO3a transfection reduced DNMT3B mRNA and protein 
expression. DNMT3B expression was reduced further by 
 co-treatment of A549 cells with doxorubicin and FOXO3a 
transfection (Fig. 1B). In contrast, FOXO3a knockdown 
induced higher mRNA and protein expression of DNMT3B 
than control in CL1-5 cells (Fig. 1C).
FOXO3a Negatively Regulates the Promoter 
Activity of DNMT3B by Binding to Its Putative 
Binding Sites in DNMT3B Promoter
We further analyzed for the presence of FOXO3a 
binding sites (consensus DNA sequence [G/C/A] [T/C/A] 
AAA [T/C] A)33 in DNMT3B promoter. Two putative 
FOXO3a binding sites (FOXO3a-P, −249 to −242 and 
FOXO3a-E, +166 to +173) in DNMT3B promoter were pre-
dicted using the PROMO software (Fig. 2A). To confirm the 
transcriptional effects of FOXO3a on DNMT3B promoter, 
we constructed three DNMT3B promoter plasmids. The 
full length promoter (−483 to +315) contains both putative 
binding sites, P region promoter (−483 to +50) contains the 
FOXO3a-P site, and E region promoter (+31 to +315) con-
tains the FOXO3a-E site (Fig. 2A).
Dual luciferase reporter assays were performed in 
A549 (Fig. 2B) and CL1-5 (Fig. 2C) cells to quantify the 
FIGURE 1.  FOXO3a represses the 
mRNA and protein levels of DNMT3B. 
A, Immunofluorescence analysis of 
A549 and CL1-5 cells treated with 
DMSO or doxorubicin. The staining 
of FOXO3a is shown in green and the 
nuclei (DAPI) in red. The intensities 
of endogenous FOXO3a in the A549 
cells are lower than that of CL1-5 cells 
(upper panel). Upon doxorubicin treat-
ment, FOXO3a translocated into the 
nuclei in both cell lines (lower panel). 
Scale bar: 10 μm. (B) DNMT3B mRNA 
and protein level in A549 cells trans-
fected with GFP-FOXO3a or treated 
with doxorubicin alone or in combina-
tion. (C) DNMT3B mRNA and protein 
level in CL1-5 cells transfected with 
si-FOXO3a or treated with doxorubi-
cin. Relative DNMT3B mRNA expres-
sion was detected by RT-qPCR and 
the quantified data are shown in the 
Y-axis. The p values are as indicated 
and were calculated by two-tailed 
student t test based on three inde-
pendent experiments (*p < 0.05; **p 
< 0.01; *** p < 0.001; upper panel). 
Quantification of relative protein levels 
on three different western blots is 
shown below the blots (lower panel).
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transcriptional regulation of FOXO3a on DNMT3B promoter 
activity. The cells were co-transfected with pGL4-renilla 
and either full length, P region or E region promoter plas-
mids. Vector control or GFP-FOXO3a expression vector 
was transfected into A549, and si-control or si-FOXO3a 
was transfected into CL1-5 cells. The data indicated that 
overexpression of FOXO3a impaired promoter activities 
of all three promoter constructs. However, the activity of P 
region promoter, which contains only the putative binding 
site FOXO3a-P, was less responsive to FOXO3a regulation 
than other promoter constructs (Fig. 2B). In contrast, knock-
down of FOXO3a significantly induced activity of full length 
and E region promoters containing the putative binding site 
FOXO3a-E and this induction was less dramatic in P region 
promoter (Fig. 2C). The data implicated that FOXO3a could 
transcriptionally repress the DNMT3B mainly through the 
putative binding site, FOXO3a-E.
We further performed ChIP assay to determine 
whether FOXO3a could directly bind to the predicted 
FOXO3a sites in DNMT3B promoter in A549 (Fig. 2D) 
and CL1-5 (Fig. 2E). Primers specific for P region (−252 
to −13) containing FOXO3a-P site and for E region (+71 
to +222) containing FOXO3a-E site were used. The data 
indicated that the basal binding level of FOXO3a to the 
P region was lower than to the E region (p = 0.031 for 
A549, lanes 1 versus 3; p = 0.047 for CL1-5, lanes 1 ver-
sus 4). However, binding to the P region could be elicited 
by enforcing abundant FOXO3a into nuclei by treatment 
with doxorubicin in both cell lines (p = 0.040 for A549, 
lanes 1 versus 2; p = 0.017 for CL1-5, lanes 1 versus 2). 
FIGURE 2.  FOXO3a binds to the DNMT3B pro-
moter containing its putative binding sites. A,  indi-
cates FOXO3a putative binding sites (FOXO3a-P 
and FOXO3a-E) and their locations are shown as 
nucleotide numbers relative to transcriptional 
start site (+1). Three different DNMT3B promoter 
constructs were generated: Full length promoter 
containing both the FOXO3a-P and FOXO3a-E 
sites, P region containing only FOXO3a-P site, and 
E region containing only FOXO3a-E site. (B) Dual 
luciferase assay was performed after cells were 
transfected with vector control or GFP-FOXO3a 
followed by promoter firefly luciferase promoter 
constructs and pGL4-renilla vector in A549 cells. 
(C) CL1-5 cells were transfected with the si-control 
or si-FOXO3a followed by promoter constructs and 
pGL4-renilla vector. (D, E) ChIP to detect FOXO3a 
binding to P and E regions of DNMT3B promoter 
in A549 and CL1-5 cells. The binding of FOXO3a 
to DNMT3B promoters was stronger at E region 
than P region when expressed at the basal level 
(lanes 1 versus 3, A549 cell; lanes 1 versus 4, CL1-5 
cell). pGFP-FOXO3a transfection and doxorubicin 
treatment led to high level of FOXO3a, which 
enhanced its binding to both P region (lanes 1 
versus 2) and E region (lanes 3 versus 4) in A549 
cells. Doxorubicin treatment alone also enhanced 
FOXO3a binding to P region (lanes 1 versus 2) 
and E region (lanes 4 versus 5) in CL1-5 cells, 
whereas the binding to both P and E regions was 
abolished by si-FOXO3a with a significant decrease 
at E region (lanes 4 versus 6). The p values are 
as indicated and were calculated by two-tailed 
student t test based on three independent experi-
ments (*p < 0.05; **p < 0.01; ***p < 0.001). n.s., 
non-significant.
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Endogenous FOXO3a bound to the E region in control cells 
(lane 3) and the binding of this region was increased by pro-
moting exogenous FOXO3a into nuclei in A549 (p = 0.011, 
lanes 3 versus 4; Fig. 2D). The binding of FOXO3a to the E 
region (lane 4) was abolished by si-FOXO3a in CL1-5 cells 
(p = 0.013, lanes 4 versus 6; Fig. 2E). Together, these data 
suggested that FOXO3a preferentially binds to the E region 
when expressed at a low level and binds to both the P and E 
regions when the nuclear expression level is high.
Binding of FOXO3a Renders DNMT3B 
Promoter to the Condense Chromatin Status
It has been reported that FOXO3a could regulate the 
transcriptional activities for downstream genes through inter-
action with other chromatin modifiers such as p300 (a his-
tone acetyltransferase).34,35 Thus, we performed ChIP using 
anti-histone deacetylase 3 (HDAC3; a corepressor), anti- 
trimethylation of histone 3 lysine 27 (H3K27me3; a chro-
matin-condensed marker), and anti-acetylation of histone 
3 lysine 9 and 14 (H3Ace; a loose chromatin marker) anti-
bodies to assess whether FOXO3a could regulate DNMT3B 
mRNA expression through chromatin remodeling. ChIP 
assays were performed for the P and E regions in A549 
(Fig. 3A) and CL1-5 (Fig. 3B) cells. The data indicated that 
the basal binding level of HDAC3 to the P region was lower 
than the E region (p = 0.039 for A549, lanes 1 versus 3; 
 p = 0.002 for CL1-5, lanes 1 versus 4), and enforcing FOXO3a 
into nuclei by doxorubicin treatment promoted the binding of 
HDAC3 to both the P and E regions (p = 0.030 and p = 0.023 
for A549, lanes 1 versus 2 and lanes 3 versus 4, Fig. 3A; 
p = 0.027 and p = 0.049 for CL1-5, lanes 1 versus 2 and lanes 
4 versus 5, Fig. 3B). In addition, the binding of HDAC3 and 
the chromatin-condensed modifications (increased binding of 
H3K27me3 and decreased binding of H3Ace) on both the P 
and E regions of DNMT3B promoter was evident by enforcing 
FOXO3a into nuclei in A549 cells (For HDAC3: p = 0.030, 
lanes 1 versus 2; p = 0.023, lanes 3 versus 4. For H3K27me3: 
p = 0.017, lanes 1 versus 2; p = 0.045, lanes 3 versus 4. For 
H3Ace: p = 0.011, lanes 1 versus 2; p = 0.035, lanes 3 ver-
sus 4 in Fig. 3A) and CL1-5 cells (For HDAC3: p = 0.027, 
lanes 1 versus 2; p = 0.049, lanes 4 vs. 5. For H3K27me3: 
p = 0.003, lanes 1 versus 2; p = 0.023, lanes 4 versus 5. For 
H3Ace: p = 0.020, lanes 1 versus 2; p = 0.014, lanes 4 ver-
sus 5 in Fig. 3B). Moreover, HDAC3 could not bind to the E 
region of DNMT3B promoter to form a repressive chromatin 
structure after FOXO3a knockdown (For HDAC3: p = 0.003, 
lanes 4 versus 6. For H3K27me3: p = 0.026, lanes 4 versus 
6. For H3Ace: p = 0.035, lanes 4 versus 6 in Fig. 3B). These 
data suggested that FOXO3a may cooperate with HDAC3 to 
bind to DNMT3B promoter and form a condensed chromatin 
structure thereby to repressing DNMT3B expression.
Inhibition of MDM2 Induces FOXO3a 
Expression Resulting in Reduction 
of DNMT3B Expression
FOXO3a is one of the substrates of E3-ubiquitin 
ligase MDM2.29 To examine whether MDM2 could regulate 
DNMT3B expression through repression of FOXO3a, we 
knocked down MDM2 and found an increase in FOXO3a 
protein expression along with a decrease in DNMT3B protein 
level in A549 cells (Fig. 4A). Furthermore, we treated cells 
with the MDM2 inhibitor, Nutlin-3, which reduced DNMT3B 
mRNA levels (Fig. 4B).
FIGURE 3.  FOXO3a modulates the chromatin modifica-
tions of DNMT3B promoter regions. ChIP for FOXO3a 
binding to DNMT3B promoter in A549 (A) and CL1-5 (B) 
cells. Antibody to HDAC3, trimethylation of histone 3 lysine 
27 (H3K27me3), and acetylation of histone 3 lysine 9 and 
14 antibodies (H3Ace) were used to immunoprecipitate 
the DNA which was then amplified to detect the P region 
and E region of DNMT3B promoter. IgG serves as a nega-
tive control. The binding of HDAC3 to DNMT3B promoter 
was stronger at E region than P region when FOXO3a was 
expressed at the basal level (lanes 1 versus 3, A549 cell; 
lanes 1 versus 4, CL1-5 cell). pGFP-FOXO3a transfection 
and doxorubicin treatment led to a repressed chromatin 
structure manifested by increased HDAC3 binding and 
H3K27me3 mark along with decreased H3Ace mark at P 
region (lanes 1 versus 2) and E region (lanes 3 versus 4) in 
A549 cells. Similar repressed chromatin status was observed 
in CL1-5 cells (lanes 1 versus 2 and lanes 4 versus 5). This 
repressed chromatin structure was abolished in si-FOXO3a 
treated CL1-5 cells especially at the E region (lanes 4 versus 
6). The p values were calculated by two-tailed student t test 
based on at least three independent experiments (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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FIGURE 4.  Co-treatment with doxorubicin and Nutlin-3 diminishes tumor growth, decreases DNMT3B expression and 
leads to demethylation of tumor suppressor genes in vitro and in vivo. A, Western blot showing knockdown of MDM2 
induced FOXO3a and reduced the protein levels of DNMT3B in A549 cells. (B) Quantitative analysis of relative DNMT3B 
mRNA expression in A549 cells treated with either doxorubicin, Nutlin-3 or both drugs. All treatments reduced the 
DNMT3B mRNA expression, and co-treatment with doxorubicin and Nutlin-3 rendered the strongest reduction. The 
p values are as indicated and were calculated by two-tailed student t test based on three independent experiments. 
(C) Balb/c nude mice bearing the established A549 tumors were treated intraperitoneally with doxorubicin (1 mg/kg; 
twice per week) and/or Nutlin-3 (20 mg/kg; three times per week) for 3 weeks. The tumor volumes of mice were mea-
sured at the indicated times. Points, mean; bars: SD (n = 6). The p values are as indicated. (D) Immunohistochemical 
analysis of FOXO3a and DNMT3B protein expression in xenograft from DMSO and co-treated mice groups. Low 
expression of FOXO3a and overexpression of DNMT3B were found in DMSO control mice (xenograft 1 and 2). After 
treatment with doxorubicin and Nutlin-3 (xenograft 3 and 4), FOXO3a expression increased and DNMT3B expression 
decreased. (Original magnification × 200). (E) qMSP assay to detect methylation level of the BLU, RASSF1A, and SLIT2 
genes. β-actin is used for internal control. The methylation status of target genes versus β-actin in DMSO control is 
normalized to “1”. Doxorubicin and Nutlin-3 decreased the methylation status of the three tumor suppressor genes in 
treated xenograft. The p values are as indicated and were calculated by two-tailed student t test based on three inde-
pendent experiments. n.s., non-significant.
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Co-treatment with Doxorubicin and 
Nutlin-3 Diminishes Tumor Growth, 
Decreases DNMT3B Expression and Leads to 
Demethylation of TSGs In Vitro and In Vivo
The above findings prompted us to hypothesize that 
combination treatment with Nutlin-3 and doxorubicin could 
be a potential therapeutic strategy based on its ability to 
decrease DNMT3B expression and DNA methylation level of 
TSGs through induction of FOXO3a transcriptional activity. 
Therefore, we treated cells with either Nutlin-3 or doxorubicin 
alone or in combination. The results showed that comparing to 
cells treated with Nutlin-3 or doxorubicin alone, the combina-
tion treatment further augmented the reduction of DNMT3B 
mRNA (p < 0.001, p = 0.001, and p < 0.001 for compari-
sons between combined treatment to control, doxorubicin, 
and Nutlin-3, respectively; Fig. 4B). The combination index of 
0.615 indicated synergism between doxorubicin and Nutlin-3.
To confirm the synergistic antitumor activity of com-
bined treatment of doxorubicin and Nutlin-3 in vivo, A549-
bearing Bulb/c nude mice were injected intraperitoneally 
with doxorubicin (1 mg/kg; twice per week) and/or Nutlin-3 
(20 mg/kg; three times per week) for a total of three weeks. 
Co-treatment with doxorubicin and Nutlin-3 significantly 
inhibited tumor growth by almost 60% of tumor volume com-
pared with DMSO control (p < 0.001; Fig. 4C). Moreover, 
tumor weight of mice treated with the combination was mark-
edly reduced compared with other treatments.
To explore whether the in vivo antitumor growth activi-
ties of co-treatment with doxorubicin and Nutlin-3 resulted 
from inducing FOXO3a and reducing DNMT3B expression, 
tumor sections in xenograft from DMSO control and co-
treatment groups were collected for immunohistochemistry 
analysis of FOXO3a and DNMT3B. Combined treatment with 
doxorubicin and Nutlin-3 promoted the nucleus expression of 
FOXO3a leading to the reduction of DNMT3B expression 
(Fig. 4D, xenograft 3 and 4), whereas low FOXO3a expres-
sion accompanied with high DNMT3B expression was seen 
in DMSO control (Fig. 4D, xenograft 1 and 2).
To investigate whether the methylation status of the TSGs 
could be reversibly reduced by treatment with these drugs, we 
detected the methylation level in the promoters of three TSGs, 
including BLU, RASSF1A, and SLIT2, which had been reported 
to be hypermethylation in lung cancer cells.36–38 The validation 
and primary data of qMSP assay are shown in SDC 5 (http://
links.lww.com/JTO/A620). Combined treatment with doxorubi-
cin and Nutlin-3 significantly decreased the methylation status of 
BLU, RASSF1A and SLIT2 (p < 0.001 for comparisons between 
combined treatment and DMSO control, Fig. 4E). Together, our 
data suggested that combined treatment with doxorubicin and 
Nutlin-3 synergistically reduces the tumor growth and reverses 
the hypermethylation status of TSGs in vivo.
Lung Cancer Patients with High DNMT3B, 
Low FOXO3a and High MDM2 Expression 
Profile Correlate with Poor Prognosis
To analyze the correlation between DNMT3B, 
FOXO3a, and MDM2 expressions in lung cancer patients, 
immunohistochemistry was performed on tumor from 74 lung 
cancer patients. An inverse correlation between FOXO3a and 
DNMT3B expression, (p = 0.026) and between FOXO3a and 
MDM2 (p = 0.032) was found, whereas positive correlation 
between the DNMT3B and MDM2 expression was revealed (p 
= 0.004) (Table 1 and Fig. 5A). Importantly, the Kaplan-Meier 
survival analysis showed that lung cancer patients with high 
DNMT3B, low FOXO3a, and high MDM2 expression profile 
correlated with worse prognosis (p = 0.027; Fig. 5B). Together, 
these data suggested that the signature of a DNMT3B high, 
FOXO3a low, and MDM2 high expression profile correlated 
with poor survival and may serve as a prognostic marker in 
patients with lung cancer.
DISCUSSION
It is a challenging question as to how the expression of 
DNMTs is regulated in normal cells and dysregulated in tumor 
cells. Our previous studies show the transcriptional deregula-
tion of DNMT1 by p53 and DNMT3A by RB.39,40 Here, we 
reveal a new mechanism that FOXO3a binds to the FOXO3a-E 
region of the DNMT3B promoter to repress DNMT3B expres-
sion when FOXO3a is expressed at low level (Fig. 5C). 
Enforcing abundant FOXO3a to nuclei by doxorubicin or 
TABLE 1.  Correlation Between DNMT3B, FOXO3a, and MDM2 Protein Expression in Lung Cancer Patientsa
Characteristics
 DNMT3B Protein  MDM2 Protein
Normal 
Expression Over expression Normal Expression
Over 
expression
Total N (%)b N (%)b Total N (%)b N (%)b
Overall 74 33 (44.6) 41 (55.4) 74 29 (39.2) 45 (60.8)
FOXO3a protein FOXO3a protein
  Low expression 42 14 (33.3) 28 (66.7)0.026   Low expression 42 12 (41.4) 30 (66.7)0.032
  Normal expression 32 19 (59.4) 13 (40.6)   Normal expression 32 17 (58.6) 15 (33.3)
DNMT3B protein
  Overexpression 41 10 (34.5) 31 (68.9)0.004
  Normal expression 33 19 (65.6) 14 (31.3)
aThese results were analyzed by the χ2 test. The p values with significance are shown as superscripts.
bNumber (N) and percentage (%) of patients analyzed. 
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Nutlin-3 treatment further binds to the FOXO3a-P region 
leading to the formation of condensed chromatin structure and 
DNMT3B silencing (Fig. 5D). This regulation can be attenu-
ated by MDM2 overexpression in lung cancer cells (Fig. 5E). 
The present study provides a new dimension for dissecting 
the deregulation of DNMT3B expression by FOXO3a/MDM2 
regulation control. Co-treatment with Nutlin-3 and doxorubi-
cin may inhibit tumor growth through epigenetic modulation, 
a novel molecular pharmacology mechanism.
It has been reported that FOXO3a functions as a tran-
scription factor that could directly bind to the promoter of the 
downstream regulated genes. In general, FOXO3a acts as a 
transcriptional activator by interacting with some co-activa-
tors, such as p300.34,35 However, there are evidences showing 
that FOXO3a could suppress downstream target genes.23,24 
Our ChIP results suggested that FOXO3a could coordinate 
with HDAC3 to form a repressive complex that transcrip-
tionally suppresses DNMT3B expression. HDAC3 belongs to 
class I HDACs, which have been reported to localize in the 
nucleus and play crucial roles in transcriptional regulation.41 
To verify whether HDAC3 could coordinate with FOXO3a to 
transcriptionally repress DNMT3B expression, we determined 
the DNMT3B mRNA and protein expression in CL1-5 cells 
after knock down of either FOXO3a or HDAC3 or both pro-
teins. The data indicated that both FOXO3a and HDAC3 were 
involved in transcriptionally repressing DNMT3B expression 
(SDC 6, http://links.lww.com/JTO/A621). Further studies 
are needed to verify the interaction between FOXO3a and 
HDAC3, and perhaps other chromatin modifiers. For exam-
ple, a study demonstrated that FOXO3a can interact with 
SIRT1 protein, a class III HDAC, leading to deacetylation of 
FOXO3a thereby attenuating the transcriptional regulatory 
activities of FOXO3a.42 In addition, FOXO3a may be a target 
of miR-155 for gene silencing in breast cancer and miR-155 is 
considered an “oncomir.” Upregulation of miR-155 has been 
reported to correlate with poor prognosis in lung cancer.43,44 
Whether miR-155 could regulate DNMT3B expression is 
worthy of further investigation.
FIGURE 5.  Patients with DNMT3B high, FOXO3a low, and MDM2 high expression profile correlate with poor survival. 
(A) The representative immunohistochemistry figures for DNMT3B, FOXO3a and MDM2 are shown for two lung cancer 
patients. FOXO3a nuclear positive immunoreactivity (+) and DNMT3B and MDM2 negative nuclear immunoreactivity 
(−) were found in patient 1, whereas patient 2 showed reverse expression pattern. (Original magnification × 200) Arrows 
indicate the magnified area (magnification × 450) of the original figures. (B) Kaplan-Meier survival curves shows that the 
patients with a profile of DNMT3B high, FOXO3a low, and MDM2 high expression correlate with worse overall survival 
compared with other patients. (C–E) Model for the transcription regulation mediated by FOXO3a in relation to doxorubicin 
and MDM2 controls on DNMT3B promoter. (C) FOXO3a at low basal level preferentially binds on the E site (+166 to +173) 
of DNMT3B promoter and leads to repression of DNMT3B mRNA and protein expression levels. (D) This negative regula-
tion can be enhanced by abundant FOXO3a nuclear expression when cells are treated with doxorubicin or MDM2 inhibitor. 
Abundant FOXO3a will be recruited to the distal putative binding site, P site (−249 to −242). (E) Transcriptional repression 
of DNMT3B expression by FOXO3a can be diminished by MDM2 overexpression through ubiquitination-mediated degrada-
tion of FOXO3a protein.
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Clinically, there are contradictory reports on the prog-
nostic effect of DNMT3B overexpression. For example, 
DNMT3B status in tumors did not correspond with survival 
distribution in colorectal cancer and disease recurrence in 
prostate cancer.10,45 However, overexpressed DNMT3B sig-
nificantly correlated with shorter overall survival in B-cell 
lymphomas.46 Notably, our clinical results showed a subgroup 
of patient with gene expression signature of DNMT3B high, 
FOXO3a low, and MDM2 high expression profile correlat-
ing with poor survival. This defined signature may serve as a 
prognostic marker in patients with lung cancer. Loss of tran-
scriptional repression of DNMT3B by low FOXO3a mediated 
by high MDM2 is a clinically relevant regulator of lung cancer 
that eventually leads to poor prognosis.
Our animal study provides a novel pharmacology 
mechanism for the conventional anticancer drug, doxoru-
bicin, and target therapy drug, Nutlin-3, that could inhibit 
tumor growth through epigenetic modulation in vivo. To 
our knowledge, the dosage of individual compound in the 
combined treatment we used in this study was all below 
the previous studies, and yet we observed the synergistic 
decrease of tumor growth and the reduction of methylation 
status in TSGs. In fact, mice intraperitoneally treated with 
doxorubicin at a dose below 1.2 mg/kg every 3 days, would 
not cause significant side effects and toxicity.47 The oral dose 
reported for Nutlin-3 is 200 mg/kg, twice a day or 40 mg/kg, 
intrapeitoneally every 2 days in clinical trial studies.31 Some 
well known antitumor drugs have been reported to activate 
FOXO3a in cells through different signal transduction path-
ways, such as cisplatin (DNA damage response), paclitaxel 
(decrease AKT and increase JNK pathway), and tamoxifen 
(inhibition of PI3K/AKT pathway).48,49 These signal trans-
duction pathways could phosphorylate FOXO3a thus elicit-
ing the export of FOXO3a from nuclei into the cytoplasm. 
Note that MDM2, an E3-ubiquitin ligase, physically interacts 
with FOXO3a resulting in ubiquitin-proteasome- mediated 
degradation of FOXO3a.29 Overexpression of MDM2 has 
been demonstrated in many human cancers.50 Inhibition of 
MDM2 by Nutlin-3, an MDM2 inhibitor, also resulted in 
the downregulation of DNMT3B expression and demethyl-
ation of TSG promoters. These data further confirmed that 
FOXO3a transcriptionally represses DNMT3B expression 
and this regulation can be attenuated by MDM2 expression. 
We previously showed a link between overexpression of 
DNMT3A and deregulation of MDM2/RB control in lung 
cancer.40 In addition, DNMT1 is transcriptional suppressed 
by p53, another degradation substrate of MDM2, in lung 
cancer.39 Further investigation as to whether combination of 
Nutlin-3 with other conventional drugs or small molecular 
inhibitor could be potent therapeutic approaches to restore 
DNMT dysregulation in cancers is warranted.
In conclusion, we reveal the mechanism by which 
FOXO3a transcriptionally represses DNMT3B expression 
and this regulation can be attenuated by MDM2 overexpres-
sion in human lung cancer model. Combined treatment with 
doxorubicin and Nutlin-3 is a novel therapeutic strategy 
through epigenetic modulation warranting further investiga-
tion in lung cancer treatment.
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